TNBC
Oncology · 2020–2025
7decisions
3medicines
7carried consumer input
108individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sacituzumab govitecan Treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have progressive disease following two or more… | Mar 2025 | Not recommended | input received Rare Cancers Australia · Medical Oncology Group |
| pembrolizumab Early-stage triple-negative breast cancer (Stage II or III) in patients who have not received prior systemic therapy, treated with pembrolizumab in combination… | Jul 2023 | Recommended with restriction | 53 individuals |
| pembrolizumab Early-stage triple negative breast cancer (TNBC) in patients who have not received prior systemic therapy, treated with pembrolizumab in combination with… | Mar 2023 | Not recommended | 12 individuals Breast Cancer Network Australia · Medical Oncology Group |
| pembrolizumab Treatment of locally recurrent unresectable or metastatic triple negative breast cancer (mTNBC) in patients whose tumours express PD-L1 (CPS≥10) and who have… | Mar 2023 | Recommended with restriction | 35 individuals Breast Cancer Network Australia · Medical Oncology Group |
| sacituzumab govitecan Treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies,… | Mar 2022 | Recommended | 4 individuals Breast Cancer Network Australia · Rare Cancers Australia · Medical Oncology Group |
| sacituzumab govitecan Treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies,… | Nov 2021 | Not recommended | 4 individuals Breast Cancer Network Australia · Rare Cancers Australia · Medical Oncology Group |
| atezolizumab First-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1 (≥1% of… | Mar 2020 | Not recommended | input received Breast Cancer Network Australia · Medical Oncology Group |
Who spoke
Medical Oncology Group · Breast Cancer Network Australia · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.